Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Massimo Puoti and Carlo Perno.
Massimo Puoti
Connection Strength
1.560
Carlo Perno
  1. SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. BMC Infect Dis. 2021 Feb 17; 21(1):184.
    View in: PubMed
    Score: 0.232
  2. Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection. Transplantation. 2021 02 01; 105(2):e22-e24.
    View in: PubMed
    Score: 0.232
  3. Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. PLoS One. 2020; 15(11):e0242765.
    View in: PubMed
    Score: 0.229
  4. Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. PLoS One. 2020; 15(9):e0236311.
    View in: PubMed
    Score: 0.225
  5. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020 Sep; 81(3):e90-e92.
    View in: PubMed
    Score: 0.222
  6. Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality. Clin Infect Dis. 2021 05 18; 72(10):1868-1869.
    View in: PubMed
    Score: 0.059
  7. Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? Viruses. 2021 05 01; 13(5).
    View in: PubMed
    Score: 0.059
  8. Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. Nat Commun. 2021 01 19; 12(1):434.
    View in: PubMed
    Score: 0.058
  9. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect. 2020 10; 81(4):e11-e17.
    View in: PubMed
    Score: 0.056
  10. Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther. 2019 02; 17(2):117-128.
    View in: PubMed
    Score: 0.050
  11. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
    View in: PubMed
    Score: 0.048
  12. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
    View in: PubMed
    Score: 0.045
  13. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.